![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Cost-Effectiveness of Treating Different Stages of Genotype 1 Hepatitis C Virus (GT1-HCV) With Viekira Pak (Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir) ± Ribavirin Compared to No Treatment in the United States
|
|
|
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
SJ Johnson1, TR Juday2, JC Samp2, SE Marx2, H Parisé1, S Virabhak1, S Saab3
1Medicus Economics, Milton, 2Global Health Economics and Outcomes Research, AbbVie, Mettawa, 3Pfleger Liver Institute, Los Angeles, United States
![EASL1.gif](../images/043115/053115-3/EASL1.gif)
![EASL2.gif](../images/043115/053115-3/EASL2.gif)
![EASL3.gif](../images/043115/053115-3/EASL3.gif)
![EASL4.gif](../images/043115/053115-3/EASL4.gif)
![EASL5.gif](../images/043115/053115-3/EASL5.gif)
![EASL6.gif](../images/043115/053115-3/EASL6.gif)
![EASL7.gif](../images/043115/053115-3/EASL7.gif)
![EASL8.gif](../images/043115/053115-3/EASL8.gif)
![EASL9.gif](../images/043115/053115-3/EASL9.gif)
![EASL10.gif](../images/043115/053115-3/EASL10.gif)
![EASL11.gif](../images/043115/053115-3/EASL11.gif)
![EASL12.gif](../images/043115/053115-3/EASL12.gif)
![EASL13.gif](../images/043115/053115-3/EASL13.gif)
![EASL14.gif](../images/043115/053115-3/EASL14.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|